Industry Insights
Industry Targeted Insight
Our Commitment to Providing Value
PayerAlly is dedicated to providing our clients with a wealth of resources that keeps them up-to-date on the latest industry news, white papers, comprehensive webinars, and the work of industry thought leaders. The pharmaceutical landscape is always experiencing new challenges and changes, and our promise to you is that we consistently deliver innovative solutions that keep up with the industry's ever-changing nature.
- All Articles
- Industry Insights
- Medication Updates
The Volatility of Rebate Management
Industry Insights Rebates Changing Due to Regulatory Pressure and Evolving Drug Market Why does the model need to change? The PBM market is in a state of tremendous fluctuation. We have:payors looking to decouple pharmacy benefit management services (e.g. use of non-verticallyintegrated big 3 PBM models and using claims processing, mail service, etc from varied vendors),regulatory…
OBESITY- Is The Treatment an Epidemic
Industry Insights A white paper about the on & off-label use of the GLP-1 Agonists What is happening with the treatment of obesity? In this white paper, we will dive into the GLP-1 receptor agonists (“GLP-1”) for the treatment of obesity. Although GLP-1s have been used primarily for diabetes, we are focused on the recent…
Medical or Pharmacy Benefit
Industry Insights A white paper on the background of pharmacy vs medical coverage Managing drug spend on both benefits With the pipeline of medications and treatments being largely ultra-expensive medications overwhelmingly infused, injected or through more expansive treatment protocols like gene therapies – decisioning on where to cover these medications is now, more than ever,…
Covid Testing – Does Free Equal Frivolous?
Industry Insights A white paper concerns of waste, and coverage change What is Changing, and When? The requirement by the federal government for commercial coverage of COVID-19 tests ends May 11, 2023. While some have stated concern over a potential inability to get the testing once it is no longer free under all insurances, payers…
Sanofi Joins Lilly and Novo Nordisk to Cut Insulin Prices (Update)
Industry Insights A white paper on what this means to medication cost management What is the Update? Following suit of Lilly and Novo Nordisk, Sanofi announced price decreases and caps on their insulin products that would take effect at the beginning of next year. Price decreases would reduce list prices for Sanofi’s Apidra by 70%…
New Biosimilar for Macular Degeneration and Retinopathy | AFLIBERCEPT (Eylea)
Industry Insights Medication Update New Biosimilar for Macular Degeneration and Retinopathy Although we hear the word biosimilar commonly now in medication management, the biosimilars coming to market stretch well beyond the new biosimilar for Humira. Disease treatment moved from the use of chemical compounds to biologics years ago, and now with patent expiration, we are…
Network Audit – Results vs Remedies
Industry Insights A white paper on pharmacy audit & investigations Understanding your audit and investigative program – is it working for you? In many cases, we see our audit and investigative reports and check a box that our vendors are managing the network and preventing Fraud, Waste, and Abuse (FWA). Running a tight network audit…
New Oral Option for patients with Anemia due to CKD on Dialysis | Jesduvroq
Industry Insights Medication Update New Oral Option for patient with Anemia due to CKD on Dialysis On February 1, 2023, the FDA approved GlaxoSmithKline’s oral therapy, Jesduvroq (daprodustat), for the treatment of anemia due to chronic kidney disease (CKD) on dialysis.1 Notably, sources estimate that over 500,000 patients of the 700,000+ with end-stage CKD meet…
Lilly and Novo Nordisk to cut insulin Prices
Industry Insights A white paper on what this means to medication cost management What was the change? Both Lilly and Novo Nordisk have announced that their companies will reduce the price of several branded insulin products by as much as 75%. Novo’s decision on March 14th followed closely after Eli Lilly’s earlier announcement on March 1st to…
Manufacturer Funding Changes & Challenges
Industry Insights A white paper on the opposing thoughts on patient assistance What is happening in the world of manufacturer funding assistance? We previously wrote a white paper on the ups and downs of manufacturer funding assistance – read that article on our Industy Insights section of PayerAlly.com. Now, we are taking another step to…
Gene Therapy – “Therapy” Not Medication
Industry Insights A white paper on understanding gene therapy What is Gene Therapy? Gene therapy is all the BUZZ in conversations about medication cost control and yet it is not a medication. So what is gene therapy and what makes it different than the ‘medications’ of the past. Why should we as stewards of health…
Manufacturer Funding – The Ups & Downs
Industry Insights A white paper on manufacturer funding Why is manufacturer subsidized funding a ‘big deal’? There has been a great deal of commentary on manufacturer funding, and how plans are using the funding to do more to offset patient cost share amounts. In this white paper, we are going to give you the background…
New SGLT2 inhibitor for Diabetes Type 2 | Brenzavvy
Industry Insights Medication Update New SGLT2 inhibitor for Diabetes Type 2 On January 23, 2023, the FDA approved Brenzavvy (bexagliflozin) made by TheracosBio for the treatment of adults with type 2 diabetes.1 Brenzavvy is a SGLT2 inhibitor that lowers blood sugar by causing the removal of sugar from the body through urine.Brenzavvy is available as 20…
The Ins and Outs of PBM Audit
Industry Insights A white paper on pharmacy audit & investigations Understanding your audit and investigative program – is it working for you? In many cases, we see our audit and investigative reports and check a box that our vendors are managing the network and preventing Fraud, Waste, and Abuse (FWA). Running a tight network audit…
First biosimilar for Humira® now available | Amjevita™
Industry Insights Medication Update First biosimilar for Humira® now available Availability of Amjevita™, the first biosimilar for Humira®, rocked the headlines on January 31, 2023. Amjevita™ (adalimumab-atto), a citrate-free biosimilar to Humira® (adalimumab), is now available in the U.S.1Similar to the Humira, Amjevita carries all the same indications for:2 Rheumatoid arthritis (RA) Juvenile idiopathic arthritis…
Connect With Us Today
PayerAlly is proud to offer our clients high-quality, expert consulting and PBM services in procurement, PBM monitor Program, PBM audits, PBM benchmarking, pharmaceutical strategy consulting, clinical program development, market research, and PBM implementation management services. Reach out to us today so one of our team members can get back to you promptly.